Residency · Residency · Physical Medicine Rehabilitation
Amyotrophic Lateral Sclerosis: Rehabilitative Management
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting both upper and lower motor neurons, leading to progressive weakness, muscle atrophy, spasticity, and ultimately respiratory failure. While no cure exists, a comprehensive interdisciplinary rehabilitation approach can significantly improve quality of life, maintain function, and extend survival. Physiatrists play a central role in managing mobility, communication, nutrition, respiratory support, and symptom management throughout the disease trajectory.
Disease Overview
Pathophysiology
Degeneration of upper motor neurons (corticospinal tract) and lower motor neurons (anterior horn cells, brainstem nuclei). Progressive denervation leads to muscle weakness, atrophy, and fasciculations. UMN involvement produces spasticity, hyperreflexia, and pathologic reflexes. Median survival: 2-5 years from symptom onset; 10% survive >10 years. Riluzole and edaravone offer modest slowing of progression.
Clinical Presentations
Limb-onset (70%): Asymmetric distal weakness progressing proximally. Bulbar-onset (25%): Dysarthria and dysphagia as initial symptoms; worse prognosis. Respiratory-onset (5%): Dyspnea and orthopnea; poorest prognosis. ALS-frontotemporal dementia overlap in 10-15% of cases.
Diagnostic Criteria
Revised El Escorial criteria: Definite, probable, possible ALS based on UMN and LMN involvement. EMG/NCS: Active denervation with reinnervation changes across multiple regions. Exclusion of structural, inflammatory, and other neuromuscular conditions.
Rehabilitation Assessment
Functional Scales
ALS Functional Rating Scale-Revised (ALSFRS-R): 12-item scale (0-48); monitors functional decline. Manual Muscle Testing (MMT): Serial strength measurements to guide intervention timing. Forced vital capacity (FVC): Primary respiratory metric; monitors for ventilation needs. Rate of decline in ALSFRS-R score predicts prognosis.
Multidisciplinary Team
Physiatrist, neurologist, pulmonologist, speech-language pathologist. Physical therapist, occupational therapist, respiratory therapist. Nutritionist/dietitian, social worker, psychologist. Palliative care specialist; hospice team as appropriate. 
Mobility and Exercise
Exercise Prescription
Moderate-intensity exercise is safe and beneficial in early-to-mid stages. Avoid eccentric overload and exhaustive exercise (risk of overwork weakness). Aerobic exercise: Stationary cycling, swimming at submaximal intensity. Resistance exercise: Low-to-moderate intensity; avoid muscle groups with significant denervation. Range of motion and stretching to prevent contracture. Energy conservation and activity pacing as disease progresses.
Assistive Devices
Ankle-foot orthoses (AFOs) for foot drop. Canes, walkers progressing to power wheelchairs as weakness advances. Adaptive equipment for ADLs (built-up handles, reachers, button hooks). Home modifications: Ramps, grab bars, stairlifts, hospital bed. Timely referral for wheelchair evaluation is critical; avoid delayed prescription.
Communication Management
Dysarthria Progression
Spastic, flaccid, or mixed dysarthria depending on predominant UMN/LMN involvement. Speech therapy for compensatory strategies in early stages. Voice banking recommended early while speech is still intelligible. Voice amplification devices for reduced volume.
Augmentative and Alternative Communication (AAC)
Low-tech: Alphabet boards, communication boards. High-tech: Tablet-based speech-generating devices, eye-tracking systems. Brain-computer interfaces: Emerging technology for locked-in patients. Timely assessment and provision before communication is severely impaired.
Nutritional Management
Dysphagia
Bulbar dysfunction leads to progressive swallowing difficulty. Modified diet textures (thickened liquids, pureed foods) as recommended by SLP. Weight monitoring: Unintentional weight loss correlates with poorer prognosis. Percutaneous endoscopic gastrostomy (PEG) recommended when: FVC >50% (safer procedural risk). Significant weight loss (>10% body weight). Meal duration excessively prolonged. Aspiration risk despite diet modification.
Nutritional Goals
Maintain body weight and adequate caloric intake. High-calorie, nutrient-dense diet. Enteral nutrition via PEG does not preclude continued oral intake for pleasure. Hydration management critical throughout disease course.
Respiratory Management
Monitoring
FVC measured sitting and supine at every clinic visit. Sniff nasal inspiratory pressure (SNIP) and maximal inspiratory pressure (MIP) for diaphragm assessment. Nocturnal oximetry for early detection of hypoventilation. Symptoms: Orthopnea, morning headaches, daytime somnolence, fatigue.
Non-Invasive Ventilation (NIV)
Bilevel positive airway pressure (BiPAP) initiated when FVC <50% or symptomatic hypoventilation. Extends survival by 7-11 months and improves quality of life. Start at low pressures; titrate for comfort and efficacy. Adherence support through mask fitting, humidification, and education.
Secretion Management
Mechanical insufflation-exsufflation (CoughAssist): Assists cough clearance. Mucolytics (guaifenesin, N-acetylcysteine) for thick secretions. Anticholinergics (glycopyrrolate, atropine drops) for sialorrhea. Suction devices for oral secretion management. Botulinum toxin to salivary glands for refractory sialorrhea.
Symptom Management
Spasticity
Stretching, positioning, and range of motion exercises. Baclofen (oral or intrathecal); tizanidine; benzodiazepines. Botulinum toxin for focal spasticity affecting function or comfort.
Pain
Present in 50-70% of ALS patients; often underrecognized. Musculoskeletal pain from immobility and abnormal postures. Neuropathic pain managed with gabapentin, pregabalin, or duloxetine. Positioning optimization and seating assessment.
Pseudobulbar Affect
Involuntary laughing or crying disproportionate to emotional state. Dextromethorphan/quinidine (Nuedexta): FDA-approved treatment. SSRIs and tricyclic antidepressants as alternatives.
Depression and Anxiety
Prevalence: 10-25% depression; up to 30% anxiety. Pharmacotherapy: SSRIs preferred; avoid respiratory depressants. Psychological support and counseling for patient and caregivers.
Palliative Care and End-of-Life
Advance care planning initiated early and revisited regularly. Discussions about tracheostomy ventilation versus palliative approach. Hospice referral when appropriate; median hospice length of stay often too short. Caregiver support and respite care essential.
Key Clinical Pearls
- Multidisciplinary ALS clinic care is associated with improved survival and quality of life compared to general neurology follow-up; physiatrists are integral team members coordinating rehabilitation interventions. 2. Non-invasive ventilation (BiPAP) should be initiated when FVC falls below 50% or when symptoms of hypoventilation develop, as it extends survival by 7-11 months. 3. PEG tube placement should be performed while FVC remains above 50% to minimize procedural risk; early nutritional intervention helps maintain body weight, which is an independent prognostic factor. 4. Voice banking should be recommended early in the disease course while speech remains intelligible, as communication loss profoundly impacts quality of life.
References
- Miller RG, et al. "Practice Parameter Update: The Care of the Patient with Amyotrophic Lateral Sclerosis — Drug, Nutritional, and Respiratory Therapies (AAN)." Neurology. 2009;73(15):1218-1226.
- Bedlack RS, et al. "Approaches to Rehabilitation and Symptom Management in ALS." Phys Med Rehabil Clin N Am. 2008;19(3):507-521.
- Bourke SC, et al. "Effects of Non-Invasive Ventilation on Survival and Quality of Life in Patients with Amyotrophic Lateral Sclerosis." Lancet Neurol. 2006;5(2):140-147.
- Andersen PM, et al. "EFNS Guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis." Eur J Neurol. 2012;19(3):360-375.